Barinthus Biotherapeutics (BRNS) investor relations material

Executive summary

• Focused on developing immunotherapeutic drug candidates for autoimmune and inflammatory diseases, with lead candidate VTP-1000 in Phase 1 for celiac disease and a strategic shift away from infectious disease and oncology programs.

• Completed enrollment of 42 subjects in the Phase 1 AVALON trial for VTP-1000 in celiac disease; topline data from the MAD portion expected in Q4 2026.

• Entered a merger agreement with Clywedog to form a combined company targeting metabolic and autoimmune diseases, expected to close in H2 2026.

• The combined company will be renamed and is expected to have a cash runway through 2027, supported by existing and new investors.

Financial highlights

• Net loss for Q2 2026 was $10.6 million ($0.26 per share), improved from $21.1 million ($0.52 per share) in Q2 2025.

• Operating expenses decreased to $11.0 million in Q2 2026 from $23.3 million in Q2 2025.

• Cash, cash equivalents, and restricted cash totaled $59.6 million as of June 30, 2026.

• Stockholders’ equity was $57.1 million as of June 30, 2026.

• Accumulated deficit stood at $320.2 million as of June 30, 2026.

Outlook and guidance

• Existing cash resources expected to fund operations for at least the next 12 months; combined company expects runway through 2027.

• Topline data from the MAD portion of the Phase 1 AVALON trial for VTP-1000 expected in Q4 2026.

• Anticipates continued net operating losses as clinical development progresses and until commercialization or licensing of product candidates.

• Additional funding may be required if the merger with Clywedog is not consummated or for future development needs.

• R&D expenses for legacy infectious disease and oncology assets are expected to decrease, while autoimmune program expenses may remain stable or increase.